These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


854 related items for PubMed ID: 15576638

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury.
    Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ.
    Kidney Int; 2006 Mar; 69(6):1064-72. PubMed ID: 16528256
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
    Knier B, Cordasic N, Klanke B, Heusinger-Ribeiro J, Daniel C, Veelken R, Hartner A, Hilgers KF.
    J Hypertens; 2011 Aug; 29(8):1602-12. PubMed ID: 21610512
    [Abstract] [Full Text] [Related]

  • 6. Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling.
    Jia N, Dong P, Huang Q, Jin W, Zhang J, Dai Q, Liu S.
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):262-6. PubMed ID: 18785976
    [Abstract] [Full Text] [Related]

  • 7. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
    Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL, CIHR Multidisciplinary Research Group on Hypertension.
    Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
    [Abstract] [Full Text] [Related]

  • 8. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage.
    Niu P, Shindo T, Iwata H, Iimuro S, Takeda N, Zhang Y, Ebihara A, Suematsu Y, Kangawa K, Hirata Y, Nagai R.
    Circulation; 2004 Apr 13; 109(14):1789-94. PubMed ID: 14967720
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
    Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY.
    Circulation; 2010 Aug 17; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis.
    Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H.
    J Mol Cell Cardiol; 2000 Jan 17; 32(1):73-83. PubMed ID: 10652192
    [Abstract] [Full Text] [Related]

  • 11. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
    Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M, Matsumoto T.
    Circ Res; 2008 Jan 04; 102(1):68-76. PubMed ID: 17967781
    [Abstract] [Full Text] [Related]

  • 12. Circadian expression of plasminogen activator inhibitor-1 in angiotensin II type 1a receptor knockout mice.
    Tsujino T, Naito Y, Kawasaki D, Okuda S, Sakoda T, Fujioka Y, Sugaya T, Ohyanagi M.
    Clin Exp Hypertens; 2005 Jan 04; 27(2-3):159-68. PubMed ID: 15835378
    [Abstract] [Full Text] [Related]

  • 13. Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency.
    Brown NJ, Bradford J, Wang Z, Lea W, Ma L, Ma J, Vaughan DE, Fogo AB.
    Kidney Int; 2007 Jul 04; 72(1):72-81. PubMed ID: 17429342
    [Abstract] [Full Text] [Related]

  • 14. Aldosterone-and-salt-induced cardiac fibrosis is independent from angiotensin II type 1a receptor signaling in mice.
    Kagiyama S, Matsumura K, Fukuhara M, Sakagami K, Fujii K, Iida M.
    Hypertens Res; 2007 Oct 04; 30(10):979-89. PubMed ID: 18049031
    [Abstract] [Full Text] [Related]

  • 15. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension.
    Letavernier E, Perez J, Bellocq A, Mesnard L, de Castro Keller A, Haymann JP, Baud L.
    Circ Res; 2008 Mar 28; 102(6):720-8. PubMed ID: 18258859
    [Abstract] [Full Text] [Related]

  • 16. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
    Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T.
    Hypertension; 2004 Jun 28; 43(6):1195-201. PubMed ID: 15123578
    [Abstract] [Full Text] [Related]

  • 17. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart.
    Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, Law RE, Nicholas S, Ross RS, Hsueh WA.
    J Am Coll Cardiol; 2004 May 05; 43(9):1698-705. PubMed ID: 15120833
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.
    J Pharmacol Exp Ther; 2005 Aug 05; 314(2):710-6. PubMed ID: 15860572
    [Abstract] [Full Text] [Related]

  • 19. [Effects of high salt diet on blood pressure, renal morphology and osteopontin expression in Sprague-Dawley rat with Ang II-induced renal injury].
    Zheng Y, Liu ZQ, Ye T, He L, Wang Y, Fang Y, Li JN, Liu P, Ye F.
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jul 05; 25(7):827-32. PubMed ID: 16027079
    [Abstract] [Full Text] [Related]

  • 20. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
    Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ.
    Am J Hypertens; 2005 Nov 05; 18(11):1496-502. PubMed ID: 16280288
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 43.